HJKC3-0003
Phase II
OPEN TO ACCRUAL
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation